.jpg)
Vertex abandons islet cell-device combo after failing to improve diabetes biomarker
Vertex is ending work on one of its two islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.
Vertex is ending work on one of its two islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.
